Australian Pharma Warns Against Removing Orphan Fee Incentives
This article was originally published in PharmAsia News
Australia's pharmaceutical industry association, Medicines Australia, has objected to proposals by the Therapeutic Goods Administration to eliminate fee waivers for the registration and evaluation of orphan drugs. The association warns that if this incentive is removed, "local sponsors may not invest in bringing these products to market in Australia as this would not be commercially viable in many instances".
You may also be interested in...
While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.
The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.
Based on its experience of reviewing tools used by companies for additional risk minimization, the European Medicines Agency is planning to update its guidance on this topic with more information on how these tools can be better employed.